Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,891 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostate Cancer Patients Clear all
Completed Phase 1Phase 2 Interventional

A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

NCT02361086
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, CRPC
Interventions
VT-464: given orally once daily in 28 day cycles
Drug
Lead sponsor
Innocrin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated No phase listed Observational

Measuring the Effect of Radiation Therapy on Patient Activity Levels

NCT02694380
View directory record Official record
Conditions
Head and Neck Cancer, Prostate Cancer, Breast Cancer, Lung Cancer
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 30, 2026, 3:17 PM EDT
Completed No phase listed Observational

Digital PET/CT Using [Ga-68]PSMA vs. [F-18]NaF for Evaluation of Osseous Metastatic Involvement in Prostate Cancer Patients

NCT05527483
View directory record Official record
Conditions
Prostate Cancer
Interventions
[68Ga]PSMA, Flourine-18 [F-18] Sodium Fluoride (NaF), PET/CT
Drug · Diagnostic Test
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated No phase listed Observational

Long-term Study to Evaluate and Clinical Outcomes in Patients With Favorable Intermediate Risk Localized Prostate Cancer

NCT03290508
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prolaris Testing
Diagnostic Test
Lead sponsor
Myriad Genetic Laboratories, Inc.
Industry
Eligibility
65 Years and older · Male only
Enrollment
524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
34
States / cities
Homewood, Alabama • Mesa, Arizona • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2022 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 1 Interventional

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

NCT00314782
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054 (Zibotentan), Docetaxel, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Buffalo, New York • Greenville, South Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional Results available

Home-based Exercise Intervention for Patients With Metastatic Prostate Cancer

NCT03672396
View directory record Official record
Conditions
Castration-resistant Prostate Cancer, Androgen Deprivation Therapy
Interventions
Home-based exercise
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Decision Making in Unaffected First-Degree Relatives of Prostate Cancer Patients

NCT00815750
View directory record Official record
Conditions
Prostate Cancer
Interventions
Information Gathering, Decision Aid
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
40 Years to 70 Years · Male only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
2
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer

NCT00579423
View directory record Official record
Conditions
Prostate, Cancer
Interventions
QS21
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional Results available

Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer

NCT00459810
View directory record Official record
Conditions
Prostate Cancer
Interventions
transdermal estradiol, paclitaxel poliglumex
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 30, 2026, 3:17 PM EDT
Not yet recruiting Phase 2 Interventional

Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer

NCT07608718
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Zanzalintinib
Drug
Lead sponsor
Pedro Barata, MD, MSc
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 2 Interventional Results available

PSMA-PET/MRI Unfavorable-Risk Target Volume Pilot Study

NCT04176497
View directory record Official record
Conditions
Prostate Cancer
Interventions
68Ga-HBED-CC-PSMA
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer

NCT02606123
View directory record Official record
Conditions
Prostatic Neoplasms, Genital Neoplasms, Male, Genital Diseases, Male, Prostatic Diseases
Interventions
EPI-506
Drug
Lead sponsor
ESSA Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
4
States / cities
Scottsdale, Arizona • Ann Arbor, Michigan • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Oct 30, 2026, 3:17 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer

NCT00626548
View directory record Official record
Conditions
Prostate Cancer
Interventions
ZD4054, Palcebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
2,577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
38
States / cities
Tucson, Arizona • Greenbrae, California • Los Angeles, California + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Early Phase 1 Interventional Results available

Assessing Induction of Double Strand Breaks With Androgen Receptor Partial Agonist in Patients on Androgen Suppression

NCT03507608
View directory record Official record
Conditions
Prostate Cancer
Interventions
Flutamide, Placebo
Drug · Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 100 Years · Male only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Oct 30, 2026, 3:17 PM EDT
Completed No phase listed Observational

Cardiovascular Risk and Preventive Care in Prostate Cancer Patients Receiving Radiation and Hormone Therapy

NCT02003417
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
8
States / cities
Washington D.C., District of Columbia • Chapel Hill, North Carolina • High Point, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provider Training in Increasing Patient Tobacco Cessation Counseling and Referrals for Patients With Cancer Undergoing Radiation Therapy

NCT03135782
View directory record Official record
Conditions
Breast Carcinoma, Caregiver, Head and Neck Carcinoma, Lung Carcinoma, Prostate Carcinoma, Tobacco Use
Interventions
Communication Skills Training, Medical Chart Review, Questionnaire Administration, Tobacco Cessation Counseling
Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 30, 2026, 3:17 PM EDT
Not listed No phase listed Observational

The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)

NCT03896958
View directory record Official record
Conditions
Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Colon, Cancer Skin, Cancer of Cervix, Cancer, Metastatic, Cancer of Larynx, Cancer of Neck, Cancer of Lung, Cancer of Brain and Nervous System, Cancer of Vulva, Disseminated, Cancer of Pancreas, Sarcoma, GIST, Small-cell Lung Cancer, Adenocarcinoma Lung, Cancer of Prostate, Cancer, Advanced, Adrenal Cancer, Testicular Cancer, Uterine Cancer, Bronchoalveolar Cell Lung Cancer, Cancer Unknown Primary, Glioblastoma Multiforme, Oligodendroglioma, Breast Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma, Cholangiocarcinoma, Squamous Cell Carcinoma, Transitional Cell Carcinoma, Cancer, Other, Cancer, Anal, Melanoma, Cancer, Bile Duct, Cancer, Bladder, Cancer Cords Vocal, Cancers Cell Neuroendocrine, Cancer Differentiated Poorly, Cancer, Anaplastic Thyroid
Interventions
Not listed
Lead sponsor
SpeciCare
Industry
Eligibility
1 Month to 99 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Gainesville, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional

Group Therapy Compared With Educational Materials in Patients With Prostate Cancer

NCT00002848
View directory record Official record
Conditions
Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment
Interventions
psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Gary Morrow
Other
Eligibility
Male only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
7
States / cities
Phoenix, Arizona • Stanford, California • Wichita, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2013 · Synced Oct 30, 2026, 3:17 PM EDT
Not listed Not applicable Interventional

Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer

NCT01562223
View directory record Official record
Conditions
Prostate Cancer
Interventions
motexafin gadolinium
Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 3 Interventional

Cyproterone Acetate in Treating Hot Flashes Following Surgical or Chemical Castration for Prostate Cancer

NCT00005623
View directory record Official record
Conditions
Hot Flashes, Prostate Cancer
Interventions
cyproterone acetate, quality-of-life assessment
Drug · Procedure
Lead sponsor
Barr Laboratories
Industry
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Pomona, New York
Source: ClinicalTrials.gov public record
Updated Mar 26, 2013 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

NCT03418324
View directory record Official record
Conditions
Prostate Cancer
Interventions
TRC105, Abiraterone, Enzalutamide
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Gallium-68-HBED-CC-PSMA Imaging in Prostate Cancer Patients

NCT02611882
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled HBED-CC PSMA, Positron Emission Tomography (PET) image combined with Computed Tomography (CT) (PET/CT), Positron Emission Tomography (PET) image combined with Magnetic Resonance Imaging (MRI) (PET/MRI)
Drug · Device
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 3:17 PM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer

NCT02470897
View directory record Official record
Conditions
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Interventions
Radiation Therapy Treatment Planning and Simulation, SBRT
Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
Male only
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
3
States / cities
Rockford, Illinois • Johnson Creek, Wisconsin • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 3:17 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy

NCT03725761
View directory record Official record
Conditions
Prostate Cancer
Interventions
Sacituzumab Govitecan
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
3
States / cities
New York, New York • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 30, 2026, 3:17 PM EDT